FIG. 1



Screening period
(up to 6 weeks)
PF-06480605 500 mg IV Q2W
Treatment period
(12 weeks)
Baseline
Day 1
randomization
and dose
Week 2
dose
Week 4
dose
Week 6
dose
Week 8
dose
Week 10
dose
Week 12
dose
Week 14
(Primary
Assessment)
Week 16
Week 20
Week 24
Follow-up period
(14 weeks)
Week 26

FIG. 2



Assigned and treated, N=50
Induction period
PF-06480605 500 mg IV Q2W
N=50
Discontinued n=1 (2%)
AEs (1)
Follow-up period
N=49
Discontinued n=7 (14%)
Lack of efficacy (1)
Withdrawal by participant (4)
Informed consent withdrawn (2)
Completed
n=42

FIG. 3



Partial Mayo score
0
1
2
3
4
5
6
7
8
9
Week 0
Week 2
Week 4
Week 8
Week 12
Week 14
Week 20
Week 26
Visit

FIG. 4A



Serum TL1A levels at Baseline and Week 14
10000
7500
5000
2500
0
Serum TL1A (pg/mL)
Week 0
Pre Therapy
Week 14
Post Therapy
N
Y
Endoscopic Improvement
Non-Responder:
Responder:

FIG. 4B




Tissue TL1A levels at Baseline and Week 14
Tissue TL1A (ng/g)
5
4
3
2
1
N
Y
Screening
Pre Therapy
V8_Week 14
Post Therapy
Endoscopic Improvement
Non-Responder:
Responder:

FIG. 5


Innate immunity
Th17
Th1
2
Adaptive immunity
IL1β
ILC3
MHCII
OX40L
OX40
T-bet
1
IL23
Macrophage
TL1A
IBD
IL33
Dysbiosis
Mesenchyme
ILC2
4
Fibroblast
5
Th2
IL13
MMPs
3
Fibrosis
6
Anti-TL1A (PF-06480605)
Blocks innate and adaptive immunity, fibrosis and dysbiosis